The geography of coverage amplifies an ongoing problem with racial difference in access, with studies showing Black people to be less likely to receive prescriptions for GLP-1s, despite being more likely to be affected by obesity
Here are the specific verification points, based entirely on Novi's published materials
Recent Developments: In June 2025, Eli Lilly and Company entered a high-value partnership with Camurus to develop long-acting GLP-1 and dual/triple incretin therapies using Camurus proprietary FluidCrystal technology, with deal terms that could reach up to $870 million
GCs represent the standard therapy for various diseases, as well as allergic, inflammatory, rheumatoid, oncological, vascular, dermatological, and other systemic diseases [5,6,7,8]
Clinicians who broaden their diagnostic criteria and consider GLP1s within a liverfirst strategy may improve outcomes for patients who would otherwise go untreated or underdiagnosed